Back to search results

Observational Study for Cancer Risk and Malignant Neoplasm

This observational study, called Norris ORIEN Total Cancer Care, is collecting biological samples (like blood and tissue) and health information from people with cancer or those at risk for cancer. The goal is to build a large collection of data that links genetic details from samples with clinical information from medical records. Researchers hope this will help them understand why certain cancers respond to treatment differently and lead to more personalized medicine. This study is open to adults aged 18 and older who receive care at USC Norris. The study aims to collect a large number of biospecimens linked to clinical data over many years.

Study design
This is an observational study with a planned enrollment of 10,000 participants. It is not a treatment study, but rather collects information over time.
What's involved
You would provide blood samples (up to 4 times a year), extra tissue from standard surgeries, and potentially other samples like saliva or urine. You would also complete surveys about your health and lifestyle.
Compensation
Not stated in the trial record.
Follow-up
You will be followed periodically after the study, with biospecimen collection continuing for up to 21 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02970045

Norris ORIEN Total Cancer Care

Recruiting
Not specifiedAges 18+Observational
University of Southern California
~10,000 participants
Updated 2026-04-29 on ClinicalTrials.gov
What's tested:Biospecimen CollectionEvaluation of Cancer Risk FactorsMedical Chart ReviewQuality-of-Life AssessmentQuestionnaire Administration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of biospecimen collected for a centralized repository that is linked to clinical data
Measured over Up to 21 years

Conditions

Cancer Risk
Malignant Neoplasm

Explore related trials

Cancer RiskMalignant Neoplasm

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Bodour Salhia, PhD · PRINCIPAL_INVESTIGATOR · University of Southern California

Who to contact

Melissa Woodhouse, MHA, MPH
[email protected]
323-865-0489
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Limited to those patients who are registered for outpatient or inpatient care at University of Southern California (USC) Norris
Able to understand and sign the TCCP informed consent, California subject's bill of rights, Health Insurance Portability and Accountability Act (HIPAA), and research authorization form directly or through an authorized representative; the informed consent, subject's bill of rights, HIPAA, and research authorization will be available in both English and Spanish languages

Exclusion

Individuals who are not registered as patients for outpatient or inpatient care at USC Norris
Individuals who are unable to understand or sign the TCCP informed consent, subject's bill of rights, HIPAA, and research authorization in either English or Spanish

What this trial measures

  • Number of biospecimen collected for a centralized repository that is linked to clinical dataUp to 21 years

    Establish and maintain a unique repository of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected from thousands of patients 18 years of age or older who have cancer or are at risk of developing cancer.